



COPY OF PAPERS
ORIGINALLY FILED

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 47508.580 (HYZ-027CIP2))

In re Application of: Kandimalla et al.) Examiner: To Be Assigned
Serial No. 10/054,429) Group Art Unit: 1635
Filing Date: January 22, 2002)
For: COOPERATIVE OLIGONUCLEOTIDES

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date: Aug 2, 2002

Kenneth R. Maben
Kenneth R. Maben

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R., Applicant submits herewith the attached Form PTO-1449, citing 42 references in total, for filing in the above-referenced application.

This application is a continuation-in-part of U.S. Application Serial No. 08/420,672, filed April 12, 1995 (now U.S. Patent No. 6,372,427). Attached is Form PTO-1449 citing references which were already filed by Applicants or cited by an Examiner in the aforementioned application. Pursuant to 37 C.F.R. § 1.98 (d), no copies of the previously cited art are enclosed. However, copies of two references (Kabonov, *FEBS* 259:217-220 and Kandimalla, *Nucleic Acids Research* 23:3578-3584) not cited in the aforementioned application are enclosed.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to the patentability of the invention, or that the listed documents are prior art. Applicant reserves the right to take appropriate action to establish the


patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents do not constitute prior art under United States law, Applicant reserves the right to present to the Officer the relevant facts and law regarding the appropriate status of such documents.

It is respectfully requested that the Examiner initial and return copies of the enclosed form PTO-1449 with the next Patent Office communication.


This information disclosure statement is being filed under 37 C.F.R. § 1.97 (b) before the mailing date of the first Office Action. Therefore, no fee is believed to be due. However, please charge any fees which might be due to Deposit Account No. 08-0219.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,


Ann-Louise Kerner, Reg. No. 33,523
Attorney/Agent for Applicant

Date: Aug. 2, 2002
HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)



Form PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number

47508.580

Application Number

10/054,429

Applicant

Kandimalla et al.

Filing Date

January 22, 2002

Group Art Unit

1635

Sheet

1

OF

2

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,166,195	11/02.96	Ecker	514	44	

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 91/06626	16.05.91	PCT				
	WO 94/17086	04.08.94	PCT				
	WO 94/23028	13.10.94	PCT				
	WO 95/01985	19.01.95	PCT				
	0 185 494	25.06.86	EPO				
	2 225 112 A	23.05.90	Great Britain				

COPY OF PAPERS
ORIGINALLY FILED

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

C1.	Kabanov et al., (1990) <i>FEBS</i> 259:327-330
C2.	Tazawa et al., (1972) <i>J. Mol. Biol.</i> 66:115-130
C3.	Springgate et al. (1973) <i>Biopolymers</i> 12:2241-2260
C4.	Stephenson et al. (1978) <i>Proc. Natl. Acad. Sci (USA)</i> 75:285-288
C5.	Asseline et al. (1984) <i>Proc. Natl. Acad. Sci (USA)</i> 81:3297-3301
C6.	Ptashne (1986) <i>A Genetic Switch</i> ; Blackwell Scientific Publications and Cell Press: Palo Alto, CA
C7.	Maher III et al. (1987) <i>Arch. Biochem. Biophys.</i> 253:214-220
C8.	Strobel et al. (1989) <i>J. Am Chem. Soc.</i> 111:7286-7287
C9.	Distefano et al. (1991) <i>J. Am Chem. Soc.</i> 113:5901-5902
C10.	Rao et al. (1991) <i>J. Org. Chem.</i> 56:786-797
C11.	Agrawal et al. (1992) <i>Antisense Res. Dev.</i> 2:261-266
C12.	Distefano et al. (1992) <i>J. Am. Chem. Soc.</i> 114:11006-11007
C13.	Woolfe et al. (1992) <i>Proc. Natl. Acad. Sci (USA)</i> 89:7305-7309
C14.	Bayever et al. (1993) <i>Antisense Res. Dev.</i> 3:383-390
C15.	Colocci et al. (1993) <i>J. Am. Chem. Soc.</i> 115:4468-4473
C16.	Cornish et al. (1993) <i>Pharmacol. Commun.</i> 3:329-247
C17.	Gryaznov et al. (1993) <i>Nucl. Acids. Res.</i> 21:5909-5915
C18.	Distefano et al. (1991) <i>J. Am. Chem. Soc.</i> 113:5901-5902

RECEIVED

AUG 09 2002

TECH CENTER 1001 1900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
47508.580Application Number
10/054,429Applicant
Kandimalla et al.Filing Date
January 22, 2002Group Art Unit
1635

Sheet 2 OF 2

COPY OF PAPERS
ORIGINALLY FILED

C19.	Milligan et al. (1993) <i>Journal of Medicinal Chemistry</i> 36:1923:1937
C20.	Lilley et al. (1993) <i>Quarterly Rev. Biophys.</i> 26:131-175
C21.	<i>Methods Mol. Biol.</i> (1993) Vol. 20, (Agrawal, ed.) Humana Press, Totowa, NJ
C22.	Stein et al. (1993) <i>Science</i> 261:1004-1012
C23.	Colocci et al. (1994) <i>J. Am. Chem. Soc.</i> 116:785-786
C24.	Galbraith et al. (1994) <i>Antisense Res. Dev.</i> 4:201-207
C25.	Padmapriya et al. (1994) <i>Antisense Res. Dev.</i> 4:185-199
C26.	Kandimalla et al. (1995) <i>Nucleic Acids Research</i> 23:3578-3584
C27.	Rojanasakul (1986) <i>Advanced Drug Delivery Reviews</i> 18:115-131
C28.	Gura (1995) <i>Science</i> 270:575-577
C29.	Wu-Pong (1994) <i>Pharmaceutical Technology</i> 18:102-114
C30.	Stull et al. (1995) <i>Pharmaceutical Research</i> 12:465-483
C31.	Wagner et al. (1993) <i>Nature</i> 372:333-335
C32.	Stein et al. (1993) <i>Science</i> 261:1004-1012
C33.	Weiss (1991) <i>Science News</i> 139:108-109
C34.	Miller et al. (1994) <i>Parasitology Today</i> , 10:92-97
C35.	Helene, "The Antigene Strategy: Control of Gene Expression by Triplex Forming Oligonucleotides, Anti-Cancer Drug Design," 6:569-584
C36.	
C37.	
C38.	
C39.	
C40.	
C41.	
C42.	
C43.	
C44.	
C45.	
C46.	
C47.	
C48.	
C49.	
C50.	
C51.	
C52.	
C53.	
C54.	
C55.	
C56.	
C57.	
C58.	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.